Health Care Deal News, January 27, 2014 - The Fourth Quarter of 2013 Exceeded the Performance of the Third Quarter, Quest Diagnostics Last Week Announced its Acquisition of Solstas Lab Partners Group

 

Brought to you by www.DealSearchOnline.com
 

January 27, 2014 Issue:

 

Recent Health Care M&A Deals

Medical Devices

 

 

Acquirer

Target

Price

Organogenesis Inc.

Dermagraft

$0

Intuitive Surgical

Shape-sensing technology

$12 million

Pharmaceuticals

 

 

Aurobindo Pharma Limited

Actavis' Operations

N/A

Teva Pharmaceutical Industries Ltd.

Nupathe Inc.

$144 million

Par Pharmaceutical Companies, Inc.

JHP Group Holdings

$490 million

 

Technology Deal of the Week
Last month, Endo Health Solutions Inc. (NASDAQ: ENDP) announced its $105 million tender offer for NuPathe, Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on diseases of the central nervous system, including neurological and psychiatric disorders. The price represented $2.85 per share in cash upfront, and up to $3.15 per share in sales milestones for NuPathe’s primary product, migraine treatment Zecuity®. Enter Teva Pharmaceuticals Industries (NYSE: TEVA) with an offer of $3.65 per share in cash (about $144 million), and additional cash payments of up to $3.15 per share in sales milestones. Endo bowed out after receiving a $5 million termination fee from NuPathe.......Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

Charted Territory
The fourth quarter of 2013 exceeded the performance of the third quarter, when 12 deals reached or exceeded the billion-dollar mark. In the fourth quarter of 2013, all of the top deals were valued at $1.0 billion or more, compared with four billion-dollar deals announced in Q4:12. The nine deals below accounted for 70% of the total dollar volume in the fourth quarter.  


Top Transactions in Q4:13

Acquirer

Target

Price

(in millions)

Target Sector

Shire plc

ViroPharma Incorporated

$4,200

Pharmaceuticals

Bayer Group

Algeta ASA

$2,900

Pharmaceuticals

AstraZeneca plc

Global diabetes

assets

$2,700

Pharmaceuticals

Salix Pharmaceuticals, Ltd.

Santarus, Inc.

$2,600

Pharmaceuticals

CVS Caremark

Coram LLC

$2,100

Home Health Care

Royal DSM, N.V. and JLL Partners

Patheon Inc.

$1,950

Other

Grifols S.A.

Blood transfusion

diagnostics business

$1,675

Biotechnology

Endo Health Solutions Inc.

Paladin Labs Inc.

$1,600

Pharmaceuticals

Madison Dearborn Partners

Ikaria, Inc.

$1,600

Pharmaceuticals

Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today

 

Services Deal of the Week
Quest Diagnostics (NYSE: DGX) last week announced its acquisition of Solstas Lab Partners Group, a portfolio company of Welsh, Carson, Anderson & Stowe for $570 million. Solstas is a full-service commercial laboratory company based in Greensboro, North Carolina, operating in nine southeastern states. Quest expects the acquisition to add approximately 5% in annualized revenues, about 1% of which will be from professional lab services, and be modestly accretive to adjusted earnings per share in 2014........Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

In the Pipeline
Venture capitalists invested $29.4 billion in 3,995 deals in 2013, up 7% in dollar volume and 4% in deal volume, compared with 2012. That’s the word from the MoneyTree Report by PricewaterhouseCoopers LLP and the National Venture Capital Association, based on Thomson Reuters data. The Biotechnology sector saw investment dollars increase 8%, to $4.5 billion, while deal volume dropped 2%, to 470 deals in all of 2013.  The Medical Device sector fared worse, down 17% in dollar volume to $2.1 billion, and in deal volume, down 4%, to 308 deals. Together, the Biotech and Med Device sectors accounted for 23% of all VC dollars invested in 2013, compared with 25% in 2012. ....... Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

NEW - The Health Care Services Acquisition Report, 20th Edition - Preorder Today!

Deals have been made. The 2014 Health Care Services Acquisition Report contains private deals in this market that are frequently too small to make into financial press. Take advantage of our limited 2-for-1 offer - Preorder The 2014 Health Services Care Acquisition Report by January 31st and receive The 2013 Health Care Services Acquisition Report FREE ($595 value)! Now that’s a deal! Go to http://www.levinassociates.com/landing/har20order or call 800-248-1668 to preorder today.

 

Free Trial to The Health Care M&A Information Source - Get instant access to the latest issue of The Health Care M&A News
Your free trial includes 2 monthly newsletter issues, weekly email alerts to the latest deals and developments in every key segment of the health care service and technology sectors, including behavioral health care, biotechnology, e-health, home health care, hospitals, laboratories, long-term care, managed care, medical devices, pharmaceuticals, physician medical groups, rehabilitation and more.Plus, you'll receive a sample of the Health Care M&A Quartlery Report. Visit http://www.levinassociates.com/freetrialm to sign up now.

 

Around the Web in Health Care M&A...Click here to see more

 
Webcast Calendar...Click here to see more

 

Upcoming Conference Partnerships... Click here to see more